One million AspyreRx prescriptions will be delivered to patients in underserved communities disproportionately affected by type 2 diabetes.
San Francisco, March 5, 2024–(BUSINESS WIRE)–Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in the development of prescription digital therapeutics (PDT) for the treatment of cardiometabolic diseases, today announced that the American College of Lifestyle Medicine (ACLM) announced a major partnership with a number of U.S. medical institutions. Training Initiative (NTI) aims to improve diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics will fill 1 million prescriptions for AspyreRx, a U.S. Food and Drug Administration (FDA)-cleared product, to reach underserved communities through 1,400 federally qualified health center (FQHC) organizations. We are committed to being able to support our patients.
Diabetes disproportionately impacts underserved communities due to socioeconomic disparities, inadequate health care access, and systemic injustice. Despite advances in GLP-1 pharmacotherapy and the increasing availability of innovative devices such as continuous glucose monitors, the prevalence of diabetes continues to rise, and only those with diabetes are achieving glycemic control. Only about 50% of adults have it. This highlights the urgent need for evidence-based interventions to ensure everyone has equitable access to quality care.
Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions to treat chronic diseases such as cardiovascular disease, type 2 diabetes, and obesity, and when used intensively, often It can improve symptoms such as:
The Lifestyle Medicine National Training Initiative (NTI) is an extension of ACLM's $24.1 million commitment to the 2022 White House Conference on Hunger, Health, and Nutrition. We are committing more than $2 million in matching funds to train primary care providers in lifestyle medicine within each FQHC and community health center (CHC) across the United States. AspyreRx complements this important effort by helping to make scalable lifestyle medicine digital therapeutics widely accessible regardless of socioeconomic status or geographic location.
“This innovative partnership demonstrates our collective commitment to addressing disparities in health care access and accelerating the adoption of clinician training in lifestyle medicine combined with evidence-based treatments.” said Dr. Mark Berman, Chief Medical Officer of Better Therapeutics. “With our robust clinical data, including strong representation from these underserved communities, we are uniquely positioned to demonstrate the transformative potential of software-based interventions and support current behavioral programs. “We can deliver more efficient and effective treatment compared to other patients. At scale, we drive critical health outcomes in communities that often face barriers to care and are often neglected.”
AspyreRx is the only FDA-cleared, fully digital, easily accessible and scalable lifestyle intervention designed to improve outcomes in type 2 diabetes (T2D). This product is backed by robust data from randomized controlled trials (RCTs) demonstrating clinically meaningful and sustained A1c reductions and improvements in other markers of cardiometabolic health when used for 180 days. It is being RCTs have established new standards for inclusivity by actively involving participants from underserved communities. Basic characteristics include strong representation of different races and ethnicities (40% non-white), diversity in socio-economic status and education levels, and 98% live in low- or moderate-income neighborhoods. I live in
“ACLM’s work in support of the White House Challenge to End Hunger and Build Healthy Communities inspired Better Therapeutics to join us in addressing health disparities in lifestyle-related chronic diseases. We are very happy that they did so,” said Beth Frates, M.D., FACLM President of DipABLM. Faculty member at ACLM and Harvard Medical School. “By promoting lifestyle medicine training and raising awareness of evidence-based treatments that help patients make and maintain behavioral change, our joint efforts will help individuals transform food and lifestyle into medicine. We aim to help people understand the healing power they use and ultimately reduce the burden of chronic disease in communities across the country. ”
Starting in the second quarter of 2024, FQHC clinicians will have the opportunity to recommend AspyreRx to strengthen and promote healthy lifestyle behaviors, giving patients more control over their health destiny . AspyreRx implementation is scheduled to run for his two years. Better Therapeutics and ACLM are seeking additional partners and funding to support implementation and maximize the impact of this effort.
“By entering into this partnership, we will accelerate the adoption of AspyreRx and realize our vision to make society healthier and significantly reduce healthcare costs, while significantly increasing the effectiveness of ACLM's national training initiatives. We look forward to achieving this,” President Frank Calbe said. , CEO of Better Therapeutics. “Expanding access to underserved people with diabetes complements our commercial strategy as more providers gain experience with our products and generate real-world data. , it supports coverage discussions with insurance companies and can further improve the patient experience.”
About better treatments
Better Therapeutics is a prescription digital therapeutics (PDT) company developing new forms of cognitive behavioral therapy (CBT) that address the underlying factors that maintain or worsen cardiometabolic disease. We have developed a unique platform for developing FDA-regulated software-based solutions for T2D, heart disease, and other conditions. This treatment is designed to allow changes in the brain's neural pathways, allowing for permanent changes in behavior. Addressing the root causes of these diseases has the potential to dramatically improve patient health outcomes while reducing healthcare costs. Better Therapeutics' clinically validated mobile application is intended to be prescribed by doctors and reimbursed in the same way as traditional medicines.
For more information, please visit: bettertx.com
About the American Academy of Lifestyle Medicine
The American College of Lifestyle Medicine is a U.S. medical professional association that advances lifestyle medicine as the foundation for a redesigned, value-based, equitable, and value-based health care delivery system that promotes health for the whole person. ACLM engages its members through high-quality, evidence-based education, certification, and research to identify and eliminate the root causes of chronic disease, with the clinical outcome goal of restoring health rather than managing disease. We educate, equip, empower and support.
About AspyreRx
AspyreRx (formerly BT-001) received marketing approval by the FDA in July 2023 as the first prescription-only digital therapy to treat type 2 diabetes (T2D) in adults. AspyreRx is supported by robust data demonstrating clinically meaningful and sustained A1c reductions and improvements in other markers of cardiometabolic health when used for up to 180 days. AspyreRx is an engaging, self-paced experience that patients can access from their smartphones using proven technology that targets the underlying psychological, behavioral, and cognitive factors that maintain or worsen T2D . It is prescribed by your healthcare provider in 90-day increments, and your unique CBT is delivered digitally in a weekly step-by-step process. Through interactive treatment lessons, skill-building modules, and weekly goal setting and tracking, patients connect behavioral changes to improvements in blood sugar levels and other biometrics. Each step of the experience enables and strengthens cognitive restructuring based on the previous step, building the emotional resilience and acceptance needed to make lasting change.
Forward-looking statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plans” and “.” “believe”, “expect”, “anticipate”, “intend”, “outlook”, “estimate”, “predict”, “plan”, “continue”, “could”, “may” “not,” “may,” “could,” “could,” “expected,” “should,” “would” and other similar words and expressions However, the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include statements regarding Better Therapeutics' expectations regarding the efficacy and potential benefits of AspyreRx and PDT, including CBT, and their potential therapeutic uses and ability to improve clinical outcomes. but not limited to. , particularly expectations regarding the commercial traction of AspyreRx. These forward-looking statements are based on Better Therapeutics' management's current expectations and are inherently subject to uncertainties and changes in circumstances and the potential effects of such changes. Statement only as of the date of writing. There can be no guarantee that future developments will be as anticipated. These forward-looking statements are subject to a number of risks, uncertainties or other risks that could cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. Contains assumptions. risks associated with commercial distribution, market acceptance and insurance reimbursement of AspyreRx; Better Therapeutics' ability to obtain short-term financing to finance its operations and continue as a going concern; Better Therapeutics needs to explore strategic alternatives if the company is unable to raise capital. This includes, but is not limited to, the possible sale of assets or operations, transfer for the benefit of creditors, or downsizing of the company. Better Therapeutics' ability to comply with the continuing covenants under the Hercules Capital Debt Facility (including minimum cash limits) and potential defaults and foreclosures under the Debt Facility; Results of Better Therapeutics Delisting Hearing by the Nasdaq Appellate Committee and Potential Delisting from the Nasdaq Capital Market and Better Therapeutics' Form-10-Q Quarterly Report for the Fiscal Quarter Other risks and uncertainties included under the heading “Risk Factors” in our financial statements for the year ended September 30, 2023 filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2023, and thereafter. contained in the Company's filings with the SEC.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240305802584/ja/
contact address
For media inquiries, please contact info@bettertx.com.
For partnership inquiries or more information, please contact us at IR@bettertx.com.
